On Thursday it was a strong day in the markets for investors in Psycheceutical Bioscience Inc (OTCMKTS:BWVI) as the company’s stock came into focus in a big way and ended up with gains of as much as 8%. The bioscience company is involved in the development of advanced brain delivery technologies for mental health treatments.
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD
Yesterday, the company announced that it had concluded its pre-Investigational New Drug meeting with representatives of the United States Food and Drug Administration. More importantly, the company noted that the feedback it received with regard to its unique NovelDirect tropical formulation for ketamine had been positive. Hence, it was perhaps no surprise that the stock jumped on Thursday.
It could be a good move from investors to keep an eye on the Psycheceutical Bioscience stock this morning and watch for further action if any.
On the other hand, it was further noted that the regulatory agency had also provided the company with the necessary guidance with regards to the development plans pertaining to the clinical studies. Mental health is a major issue in large parts of the world at this point in time and millions suffer from it one way or another.
